Barigen 4 mg is an oral, targeted small-molecule disease-modifying antirheumatic and immunomodulatory agent manufactured by General Pharmaceuticals Ltd. Each film-coated tablet contains $mg$ of baricitinib, a potent, selective, and reversible inhibitor of the intracellular enzymes Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2).

Barigen 4 mg is formulated to serve as a clinically bioequivalent alternative to the reference brand-name drug Olumiant®. It is prescribed internationally for adult patients suffering from severe autoimmune conditions, including severe alopecia areata and moderate-to-severe active rheumatoid arthritis, as well as specific hospitalized patients with severe COVID-19-associated systemic inflammation under authorized clinical guidelines.

Due to its targeted mechanism of action, Barigen 4 mg modulates the intracellular signaling cascades of multiple inflammatory cytokines, helping to suppress immune-mediated tissue destruction, relieve joint inflammation, and restore hair follicle immune privilege.

Product Specification	Clinical Detail
Brand Name	Barigen 4 mg
Generic Name	Baricitinib
Strength	$mg4\text{ mg}$ per tablet
Dosage Form	Film-coated tablet (oral administration)
ATC Code	L04AF02 (Selective Immunosuppressants)
Chemical Formula	$C16H17N7O2S\text{C}_{16}\text{H}_{17}\text{N}_7\text{O}_2\text{S}$
Molecular Weight	$371.42\text{ g/mol} 371.42$
Manufacturer	General Pharmaceuticals Ltd. (Gazipur, Bangladesh)
Packaging Presentation	Box of 30 tablets ( $\times 103 \times 10$ Alu-Alu blister packaging)
Regulatory Category	Prescription-Only Medicine (Requires valid medical prescription)
Dispensing Verification	Identity and prescription review is mandatory before dispatch

What Is Barigen 4 mg Used For?

Barigen 4 mg is approved for specific, chronic autoimmune conditions and acute hyperinflammatory states where first-line conventional therapies have proven inadequate, intolerable, or medically contraindicated.

Severe Alopecia Areata in Adults

Barigen 4 mg is indicated for the treatment of severe alopecia areata in adult patients. Alopecia areata is an autoimmune disorder in which cytotoxic T lymphocytes attack hair follicle bulb cells, disrupting normal anagen growth and resulting in patchy, total (alopecia totalis), or universal (alopecia universalis) hair loss.

Target Patient Population: Adult patients presenting with $≥50%\ge 50\%$ scalp hair loss as quantified by the Severity of Alopecia Tool (SALT score $≥50\ge 50$ ), with or without substantial loss of eyebrows and eyelashes.
Clinical Purpose: By inhibiting JAK1/JAK2 signaling, baricitinib neutralizes interferon-gamma ( $IFN-γ\text{IFN-}\gamma$ ) and interleukin-15 (IL-15) signaling cascades, halting T-cell-mediated follicular destruction and enabling hair regrowth.

Moderate-to-Severe Active Rheumatoid Arthritis (RA)

Barigen is prescribed for adults suffering from active, moderate-to-severe rheumatoid arthritis who have had an inadequate clinical response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs), including methotrexate, or biological therapies such as tumor necrosis factor (TNF) antagonists.

Target Patient Population: Adult patients with persistent joint swelling, morning stiffness, elevated acute-phase reactants (CRP, ESR), and progressive joint erosion despite standard synthetic DMARD therapy.
Clinical Purpose: Barigen may be administered as monotherapy or in combination with methotrexate to suppress inflammatory joint synovitis, reduce radiographic progression of structural joint damage, and improve physical function.

Severe COVID-19 in Hospitalized Adults (Under Clinical Protocols)

In international emergency protocols and authoritative clinical guidelines (including those of the World Health Organization and the US National Institutes of Health), baricitinib is indicated for hospitalized adults with severe COVID-19 pneumonia.

Target Patient Population: Hospitalized adult patients requiring supplemental oxygen, high-flow nasal cannula, noninvasive positive pressure ventilation, or invasive mechanical ventilation/ECMO.
Clinical Purpose: Baricitinib suppresses the systemic hyperinflammatory cytokine storm (characterized by elevated IL-6, ferritin, and acute-phase reactants) when co-administered with systemic corticosteroids (e.g., intravenous dexamethasone).

NOTE

Important Indication Boundaries: Barigen 4 mg is not indicated or recommended for pediatric patients with alopecia areata or rheumatoid arthritis. It is not an oncology chemotherapy agent, nor is it indicated for localized, mild, or non-autoimmune forms of hair loss, such as androgenetic alopecia (male/female pattern baldness) or telogen effluvium.

How Does Barigen 4 mg Work? (Mechanism of Action)

The active ingredient in Barigen, baricitinib, is an orally active, selective, and reversible inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2).

The JAK-STAT Signaling Cascade

In healthy physiology, the Janus kinase family of intracellular enzymes (comprising JAK1, JAK2, JAK3, and TYK2) operates as catalytic relays downstream of type I and type II cytokine receptors on cell membranes. When pro-inflammatory cytokines bind their respective surface receptors, receptor-associated JAKs undergo transphosphorylation and activate downstream Signal Transducers and Activators of Transcription (STAT) proteins. Once phosphorylated, STAT dimers translocate into the cell nucleus to initiate transcription of pro-inflammatory effector genes.

Selective Enzymatic Inhibition

In autoimmune pathologies, this signaling pathway becomes chronically hyperactive. Baricitinib binds with high affinity to the ATP-binding pocket of JAK1 and JAK2:

Enzyme Potency: In cell-free kinase assays, baricitinib demonstrates approximately 100-fold greater inhibitory potency against JAK1 and JAK2 compared to JAK3, preserving essential JAK3-mediated natural killer (NK) cell functions to a greater extent than non-selective pan-JAK inhibitors.
Cytokine Downregulation: By interrupting JAK1/JAK2 activation, baricitinib halts the downstream phosphorylation of STAT1, STAT3, and STAT5. This selectively suppresses cellular signaling for critical mediators of autoimmunity, including:
- Interferon-gamma ( $IFN-γ\text IFN-\gamma$ ): The primary cytokine driving CD8+ T-cell attacks on the hair follicle bulb in alopecia areata.
- Interleukin-6 (IL-6): A key driver of synovial inflammation, pannus formation, bone erosion, and systemic acute-phase reactions in rheumatoid arthritis.
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): A cytokine responsible for myeloid cell activation and chronic tissue inflammation.

Dosage and Administration Guidelines

Prescriber Authority: The dosing regimens below are established in official prescribing information for baricitinib. Individual dosing, monitoring schedules, and dose adjustments must be determined strictly by a licensed treating physician based on clinical response, renal function, and routine laboratory tests.

General Administration Instructions

Route: Oral administration only.
Timing: Barigen 4 mg should be swallowed whole once daily with water, with or without food. Meals with high fat content do not clinically alter the systemic absorption or bioavailability of baricitinib.
Missed Dose: If a scheduled dose is missed, the patient should take it as soon as remembered on that day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Two doses must never be taken simultaneously to compensate for a missed tablet.

Dosage Adjustments for Renal Impairment

Because baricitinib is primarily eliminated via renal excretion (75%~75\% $75%$ , with $69%69\%$ excreted unchanged in urine), dosage must be adjusted according to estimated Glomerular Filtration Rate (eGFR):

Renal Function Category	eGFR Range ( $m²\text{mL/min/1.73 m}^2$ )	Severe Alopecia Areata Regimen	COVID-19 Regimen	Rheumatoid Arthritis Regimen
Normal Renal Function	$≥60\ge 60$	$4\text{ mg} 4$ once daily	$4\text{ mg} 4$ once daily	$mg2\text{ mg}$ to $mg4\text{ mg}$ once daily
Moderate Impairment	$<6030\text{ to }<60$	Reduce to $mg2\text{ mg}$ once daily.	Reduce to $mg2\text{ mg}$ once daily.	Reduce to $mg1\text{ mg}$ or $mg2\text{ mg}$ once daily.
Severe Impairment	$<3015\text{ to }<30$	Not recommended	Reduce to 1 mg $mg1\text{ mg}$ once daily	Not recommended
End-Stage / Dialysis	$< 15$	Contraindicated	Contraindicated	Contraindicated

Dosage Adjustments for Drug Interactions

Strong Organic Anion Transporter 3 (OAT3) Inhibitors: Co-administration of baricitinib with strong OAT3 inhibitors (e.g., probenecid) approximately doubles the plasma area under the curve ( $AUC\text{AUC}$ ) of baricitinib. For patients taking probenecid, the dose of Barigen must be decreased by $50\%50\%50\%$ (e.g., reduced from $mg4\text{ mg}$ once daily to $mg2\text{ mg}$ once daily).

Mandatory Clinical Laboratory Cutoffs

Prior to initiating Barigen 4 mg and during ongoing therapy, complete blood counts (CBC), liver enzymes, and lipid panels must be monitored. Therapy must be interrupted or not started if:

Absolute Neutrophil Count (ANC): $1{,}000\text{ cells/mm}^3$ (or $500\text{ cells/mm}^3$ in hospitalized COVID-19 patients).
Absolute Lymphocyte Count (ALC): $500\text{ cells/mm}^3$ (or $200\text{ cells/mm}^3$ in hospitalized COVID-19 patients).
Hemoglobin ( $Hb\text{Hb}$ ): $8\text{ g/dL} < 8$ .
Hepatic Transaminases (ALT/AST): If clinically significant drug-induced liver injury or increases $≥5×ULN\ge 5 \times \text{ULN}$ occur.

Side Effects and Safety Information

Like all systemic immunosuppressive medications, Barigen 4 mg can cause adverse reactions ranging from mild, transient symptoms to severe, life-threatening complications.

Common Adverse Reactions ( $≥2%\ge 2\%$ Incidence)

Clinical trials evaluating baricitinib demonstrated the following frequent side effects:

Upper Respiratory Tract Infections: Nasopharyngitis, pharyngitis, sinusitis, and rhinitis.
Metabolic Changes: Hypercholesterolemia (dose-related elevations in total cholesterol, LDL-C, HDL-C, and serum triglycerides). Lipid profiles should be assessed 12 weeks after initiating therapy.
Gastrointestinal Symptoms: Nausea, abdominal discomfort, and mild diarrhea.
Dermatological Effects: Acneiform eruptions, folliculitis, and urticaria.
Infections: Herpes zoster (shingles) reactivation and simple herpes simplex flare-ups.
Laboratory Elevations: Increases in serum creatine phosphokinase (CPK) and liver transaminases (ALT and AST).

Serious Adverse Events and Clinical Warnings

Opportunistic & Serious Infections: Due to suppression of JAK-dependent immune pathways, patients have developed pneumonia, cellulitis, active pulmonary or extrapulmonary tuberculosis, invasive candidiasis, and cryptococcal disease. Treatment should be paused if a patient develops any serious infection until it is controlled.
Venous Thromboembolism (DVT / PE): Swelling, warmth, or erythema in a unilateral extremity (symptoms of Deep Vein Thrombosis) or sudden unexplained shortness of breath, pleuritic chest pain, and hemoptysis (symptoms of Pulmonary Embolism) require emergency hospital intervention.
Major Adverse Cardiovascular Events: Prescribers must evaluate baseline cardiovascular risks (hypertension, hyperlipidemia, smoking history, prior myocardial infarction). Any sudden chest pressure, radiating arm pain, or signs of stroke require immediate medical cessation.
Gastrointestinal Perforations: Rare occurrences of gastrointestinal perforation have been reported with JAK inhibitors, primarily in patients with concurrent diverticulitis or those taking concomitant non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.

Drug Interactions

A thorough medication reconciliation must be conducted before initiating Barigen 4 mg.

Important Precautions & Special Populations

Pregnancy, Contraception, and Teratogenic Potential

Pregnancy Category: Based on animal reproductive studies, baricitinib crosses the placental barrier and can cause fetal harm (skeletal malformations and decreased birth weights observed at exposures comparable to human therapeutic doses).
Females of Reproductive Potential: Pregnancy status must be confirmed negative before starting Barigen 4 mg. Females of childbearing age must use reliable, effective contraception during treatment and continue contraception for at least one week after taking the final dose.
Nursing Mothers: It is unknown whether baricitinib is excreted in human breast milk, though excretion has been demonstrated in lactating animal models. Because of the potential for serious adverse reactions in nursing infants (immunosuppression, neutropenia), breastfeeding is not recommended during therapy and for at least one week following treatment discontinuation.

Pediatric Population

The safety and therapeutic efficacy of Barigen in pediatric patients ( $age<18\text{ years of age}$ ) have not been established in alopecia areata or rheumatoid arthritis. It should not be administered to children or adolescents.

Geriatric Population ( $Age\ge 65\text{ Years of Age}$ )

Clinical studies demonstrate that patients aged 65 years and older exhibit higher baseline incidences of serious infections, malignancies, and cardiovascular events when treated with JAK inhibitors. Prescribers should exercise heightened caution, monitor renal clearance regularly, and consider starting with a lower dosage ( $mg2\text{ mg}$ ) when clinically appropriate.

Baseline Screening Mandate

Before prescribing Barigen 4 mg, clinicians must complete:

Tuberculosis Screening: Purified Protein Derivative (PPD) skin test or Interferon-Gamma Release Assay (IGRA). If latent TB is identified, standard preventive anti-mycobacterial therapy must be started before baricitinib initiation.
Viral Hepatitis Panel: Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis C antibody (anti-HCV).
Fasting Lipid Profile: Establish baseline total cholesterol, LDL, HDL, and triglycerides.

Storage, Stability, and Handling

Storage Temperature: Store Barigen 4 mg tablets below $30∘C30^\circ\text{C}$ ( $86∘F86^\circ\text{F}$ ) in a dry environment.
Moisture and Light Protection: Keep tablets in their original Alu-Alu blister packaging until the moment of administration to shield them from ambient moisture, humidity, and direct sunlight.
Handling Precautions: Do not use tablets if the blister foil is torn, punctured, or shows signs of tampering.
Child Safety: Store safely out of the sight and reach of children and household pets.

Manufacturer and Quality Certification

About General Pharmaceuticals Ltd.

Barigen 4 mg is formulated and manufactured by General Pharmaceuticals Ltd. (GPL), one of the most technologically advanced pharmaceutical enterprises in Bangladesh.

Manufacturing Complex: Produced at Unit-2, located in Gazipur, Bangladesh. This facility is engineered according to international Current Good Manufacturing Practice (cGMP) standards, incorporating high-efficiency particulate air (HEPA) filtration, automated blister packaging systems, and isolated solid-dosage cleanrooms.
Quality Control Oversight: Every manufacturing lot undergoes comprehensive physicochemical testing, including High-Performance Liquid Chromatography (HPLC) assays for baricitinib purity, dissolution testing, friability inspection, and microbial limit testing.
Role Distinction: General Pharmaceuticals Ltd. acts solely as the pharmaceutical manufacturer. Selxen functions independently as an international supplier, licensed pharmaceutical platform, and dispensing service provider. Selxen secures authentic medicine supplies directly from verified manufacturing and wholesale channels, guaranteeing uncompromised supply chain integrity.

How to know the original General products?

To verify General products, check the package for a genuine verification code or scratch-off feature. Confirm the brand name, strength, batch number, manufacturing date, and expiry date. Compare these details with the company’s official product catalog. Avoid medicines with blurry printing, damaged seals, or unusual packaging. Always buy from licensed pharmacies or trusted medicine sellers. If available, use the company’s official verification system to confirm product authenticity.

Ordering, Prescription Verification, and International Supply

Selxen provides a verified, compliant supply channel for healthcare organizations, licensed distributors, and chronic patients requiring Barigen 4 mg (Baricitinib) tablets.

Supply Chain Integrity & Temperature-Controlled Shipping

All pharmaceutical products handled by Selxen are held in licensed, temperature-controlled facilities. International consignments are packed with temperature-monitoring indicators and protective insulation to ensure the medicine remains below $30∘C30^\circ\text{C}$ throughout global transit.

To check stock availability, request institutional B2B pricing, or submit a prescription for verification, contact our dedicated pharmacy support desk at selxenglobal@gmail.com or through our verified customer portal.

DISCLAIMER:
The medical information provided on this page is published exclusively for educational, clinical reference, and informational purposes. It does not constitute individual medical advice, formal clinical diagnosis, or a personalized treatment plan. Barigen 4 mg must be taken strictly under the direction and ongoing supervision of a licensed physician. Never alter, discontinue, or initiate any medical treatment without first consulting your doctor or qualified healthcare provider.

Frequently Asked Questions (FAQ)

What is the difference between Barigen 4 mg and Olumiant 4 mg?

Barigen 4 mg contains the identical active pharmaceutical ingredient (baricitinib, $mg4\text{ mg}$ ) as the reference innovator medication, Olumiant 4 mg. Manufactured under rigorous cGMP standards by General Pharmaceuticals Ltd., Barigen provides the same selective JAK1/JAK2 inhibition, route of administration, and clinical therapeutic efficacy as Olumiant, but at a more affordable cost for patients and international healthcare providers.

How quickly does Barigen 4 mg produce hair regrowth in severe alopecia areata?

In clinical studies of baricitinib for severe alopecia areata, initial terminal hair regrowth at the scalp, eyebrows, and eyelashes was typically documented between 12 and 16 weeks of continuous once-daily therapy. Statistically meaningful and cosmetically significant scalp coverage (SALT score $≤20\le 20$ ) is generally evaluated at 36 to 52 weeks. Treatment must be maintained as directed by a dermatologist, as cessation of JAK inhibitor therapy frequently leads to shedding of regrown hair within 8 to 24 weeks.

Can Barigen 4 mg be split or crushed?

Barigen 4 mg tablets are film-coated and formulated for intact oral ingestion to ensure accurate dosing and gastrointestinal absorption. Splitting, crushing, or chewing the tablets is not recommended in outpatient settings. In acute, hospitalized COVID-19 settings where patients cannot swallow, clinical protocols permit tablets to be dispersed in sterile water and administered via a nasogastric (NG) tube under strict medical supervision.

Why is lipid testing required during treatment with Barigen 4 mg?

Clinical trial data indicate that selective JAK inhibition with baricitinib causes dose-dependent increases in circulating serum lipids, including total cholesterol, Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), and triglycerides. Prescribers must evaluate a fasting lipid profile at baseline and approximately 12 weeks after starting Barigen. If hyperlipidemia develops, patients should be managed according to clinical guidelines for lipid-lowering therapy (e.g., statins).

Can I receive vaccinations while taking Barigen 4 mg?

Live attenuated vaccines (such as MMR, yellow fever, oral typhoid, and varicella) must not be administered immediately before or during treatment with Barigen 4 mg due to the risk of vaccine-strain infection resulting from immunosuppression. Inactivated, recombinant, or mRNA vaccines (such as annual influenza and non-live COVID-19 vaccines) are permitted, though the patient’s immune response to the vaccine may be modestly blunted.

Does Barigen 4 mg cure rheumatoid arthritis or alopecia areata?

Barigen 4 mg does not cure rheumatoid arthritis or alopecia areata. These are chronic autoimmune diseases driven by genetic and immunological factors. Barigen functions as a disease-modifying maintenance therapy that suppresses the active inflammatory cascade. When the medication is discontinued, the underlying immune dysregulation typically recurs, leading to disease flare-ups or hair shedding.

Be the first to review “Barigen 4 mg (Baricitinib) Tablets”

Reviews

There are no reviews yet.

Trending Now

Popular Products

Product Results

Need Help?

Sign In

Create an account

Reset password

Barigen 4 mg (Baricitinib) Tablets